Live Breaking News & Updates on Level 1 Dosage

Stay updated with breaking news from Level 1 dosage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Phase 1/2 Findings Highlight RGX-202's Safety, Impact on Key Duchenne Biomarkers

RGX-202, a gene therapy for Duchenne muscular dystrophy, was well tolerated with no therapy-related serious adverse effects in 3 patients who received the level 1 dosage. ....

United States , Aravindhan Veerapandiyan , Olivier Danos , Manufacturing Innovation Center , World Muscle Society , International Congress , Arkansas Children , North Star Ambulatory Assessment , Innovation Center , Rgx 202 , Duchenne Muscular Dystrophy , Level 1 Dosage , Serum Creatine Kinase , Affinity Duchenne ,